13F data as of 2024-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

02083G100

FAQ

Who are the top institutional investors holding ALPINE IMMUNE SCIENCES INC (NVLSEUR)?

Major stakeholders currently include Decheng Capital LLC ($329.7M), Avoro Capital Advisors LLC ($228.9M), BlackRock Inc. ($141.7M). Based on the latest 13F filings, there are a total of 180 tracked investment funds and institutions maintaining positions in NVLSEUR.

What is the overall institutional sentiment toward NVLSEUR recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $1.4B, driven by 36 managers accumulating shares while 14 reduced their exposure.

Which institutions have been selling or reducing their NVLSEUR positions?

In the latest period, 10 funds trimmed their holdings, and 4 managers completely exited their positions. The aggregate reported sell value was $227.8M.

Are there any notable investors adding NVLSEUR to their portfolios?

Yes, buying activity remains notable. 10 institutions opened new positions in {ticker}, and 26 existing holders added to their shares. The total reported buy value for the quarter amounted to $520.3M.